SCHEMBL29589

SCHEMBL29589

O=C(O)CP(=O)(O)OS

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13733831 0.77
SCHEMBL5058344 0.77 EGLN1 (0.35)
SCHEMBL560738 0.76
SCHEMBL5060575 0.75 GRM8 (0.38)
SCHEMBL5488569 0.74
SCHEMBL28292374 0.74 MEN1 (0.50)
SCHEMBL3457874 0.74
SCHEMBL28695264 0.74 MEN1 (0.50)
Hydrochloric Acid SCHEMBL27933376 0.74 MEN1 (0.50)
SCHEMBL4475592 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735603-A2 GUIDE RNA COMPOSITIONS nChroma Bio, Inc. (US) 2026-05-06 EP claimed
WO-2026090528-A2 CIRCULARLY STRUCTURED GUIDE RNAS FOR CRISPR GENOME EDITING UNIVERSITY OF MASSACHUSETTS (US) 2026-04-30 WO claimed
EP-4720304-A2 IMPROVED MODULAR PRIME EDITING WITH MODIFIED EFFECTORS AND TEMPLATES University of Massachusetts (US) 2026-04-08 EP claimed
EP-4713458-A2 COMPOSITIONS AND METHODS FOR REGULATING EXPRESSION OF ATXN2 Riboway Therapeutics, Inc. (US) 2026-03-25 EP claimed
EP-4709860-A1 COMPOSITIONS AND METHODS FOR IMPROVED GENOME EDITING WITH NME2CAS9 AND NME2-SMUCAS9 VARIANTS University of Massachusetts (US) 2026-03-18 EP claimed
US-20260009032-A1 ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS UNIV MASSACHUSETTS (US) 2026-01-08 US claimed
US-20250320496-A1 MODULATION OF ABCB11 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS CAMP4 THERAPEUTICS CORPORATION 2025-10-16 US claimed
EP-4627084-A1 MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS Camp4 Therapeutics Corporation (US) 2025-10-08 EP claimed
US-20250290072-A1 MODULATION OF SYNGAP1 GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS CAMP4 THERAPEUTICS CORPORATION 2025-09-18 US claimed
EP-4605534-A1 CONJUGATES OF SIRNA AND ANTISENSE OLIGONUCLEOTIDES (SIRNASO) AND METHODS OF USE IN GENE SILENCING University of Massachusetts (US) 2025-08-27 EP claimed
WO-2017091630-A1 TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-06-01 WO claimed
US-20170058298-A1 COMPOUNDS AND METHODS FOR CRISPR/CAS-BASED GENOME EDITING BY HOMOLOGOUS RECOMBINATION AGILENT TECHNOLOGIES, INC. 2017-03-02 US claimed
US-20160289675-A1 Guide RNA with chemical modifications AGILENT TECHNOLOGIES, INC. 2016-10-06 US claimed
US-20160215275-A1 Chemically Ligated RNAs for CRISPR/Cas9-lgRNA Complexes as Antiviral Therapeutic Agents ZHONG MINGHONG (US) 2016-07-28 US claimed
WO-2016089433-A1 GUIDE RNA WITH CHEMICAL MODIFICATIONS AGILENT TECHNOLOGIES, INC. (US) 2016-06-09 WO claimed
US-9181551-B2 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) SIRNA THERAPEUTICS, INC. (US) 2015-11-10 US claimed
US-20150291957-A1 METHODS AND COMPOSITIONS TO PRODUCE ss-RNAi ACTIVITY WITH ENHANCED POTENCY SMITH LARRY J (US) 2015-10-15 US claimed
US-20150267200-A1 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) SIRNA THERAPEUTICS, INC. (US) 2015-09-24 US claimed
WO-2014066915-A2 METHODS AND COMPOSITIONS TO PRODUCE SS-RNAI ACTIVITY WITH ENHANCED POTENCY SMITH LARRY J (US) 2014-05-01 WO claimed
US-20100015708-A1 RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF MDRNA, INC. (US) 2010-01-21 US claimed